Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

被引：0

作者：

Joyce O’Shaughnessy

Adam Brufsky

Hope S. Rugo

Sara M. Tolaney

Kevin Punie

Sagar Sardesai

Erika Hamilton

Delphine Loirat

Tiffany Traina

Roberto Leon-Ferre

Sara A. Hurvitz

Kevin Kalinsky

Aditya Bardia

Stephanie Henry

Ingrid Mayer

Yanni Zhu

See Phan

Javier Cortés

机构：

[1] Texas Oncology-Baylor Charles A. Sammons Cancer Center,Medical Oncology

[2] University of Pittsburgh Medical Center,Magee

[3] University of California San Francisco Helen Diller Family Comprehensive Cancer Center,Womens Hospital and the Hillman Cancer Center

[4] Dana-Farber Cancer Institute,Department of Medicine

[5] Leuven Cancer Institute,Medical Oncology

[6] University Hospitals Leuven,Department of General Medical Oncology and Multidisciplinary Breast Centre

[7] The Ohio State University Comprehensive Cancer Center,Medical Oncology Department and D3i

[8] Sarah Cannon Research Institute/Tennessee Oncology,Department of Oncology

[9] Institut Curie,Medical Oncology

[10] Memorial Sloan Kettering Cancer Center,Department of Hematology/Oncology

[11] Mayo Clinic,Department of Oncology

[12] University of California,Hematology, Radiotherapy, and Nuclear Medicine

[13] Los Angeles,Breast Cancer Program, Division of Hematology/Oncology

[14] Jonsson Comprehensive Cancer Center,Department of Biostatistics

[15] Columbia University Irving Medical Center,Department of Clinical Development

[16] Massachusetts General Hospital Cancer Center,International Breast Cancer Center

[17] Harvard Medical School,undefined

[18] CHU UCL Namur,undefined

[19] Vanderbilt-Ingram Cancer Center,undefined

[20] Gilead Sciences,undefined

[21] Inc.,undefined

[22] Gilead Sciences,undefined

[23] Inc.,undefined

[24] Quironsalud Group,undefined

[25] Winship Cancer Institute,undefined

[26] Emory University,undefined

来源：

Breast Cancer Research and Treatment | 2022年 / 195卷

关键词：

Sacituzumab govitecan; Antibody–drug conjugate; Cyclin-dependent kinase inhibitor;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：127 / 139

页数：12

共 50 条

[1] Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
O'Shaughnessy, Joyce
Brufsky, Adam
Rugo, Hope S.
Tolaney, Sara M.
Punie, Kevin
Sardesai, Sagar
Hamilton, Erika
Loirat, Delphine
Traina, Tiffany
Leon-Ferre, Roberto
Hurvitz, Sara A.
Kalinsky, Kevin
Bardia, Aditya
Henry, Stephanie
Mayer, Ingrid
Zhu, Yanni
Phan, See
Cortes, Javier
BREAST CANCER RESEARCH AND TREATMENT, 2022, 195 (02) : 127 - 139
[2] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Bardia, A.
Hurvitz, S. A.
Tolaney, S. M.
Loirat, D.
Punie, K.
Oliveira, M.
Brufsky, A.
Sardesai, S. D.
Kalinsky, K.
Zelnak, A. B.
Weaver, R.
Traina, T.
Dalenc, F.
Aftimos, P.
Lynce, F.
Diab, S.
Cortes, J.
O'Shaughnessy, J.
Dieras, V
Ferrario, C.
Schmid, P.
Carey, L. A.
Gianni, L.
Piccart, M. J.
Loibl, S.
Goldenberg, D. M.
Hong, Q.
Olivo, M. S.
Itri, L. M.
Rugo, H. S.
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16): : 1529 - 1541
[3] Sacituzumab govitecan in triple-negative breast cancer
de Nonneville, Alexandre
Goncalves, Anthony
Mamessier, Emilie
Bertucci, Francois
ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (11)
[4] Tackling metastatic triple-negative breast cancer with sacituzumab govitecan
Schreiber, Anna R.
Andress, Michelle
Diamond, Jennifer R.
EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (12) : 1303 - 1311
[5] Sacituzumab Govitecan for treating Patients with metastatic triple-negative Breast Cancer
Lorenz, Judith
GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (12) : 1271 - 1271
[6] A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer
Bardia, Aditya
Hurvitz, Sara A.
Rugo, Hope S.
Brufsky, Adam
Cortes, Javier
Loibl, Sibylle
Piccart, M.
Cowden, Janice
Spears, Patty
Carey, Lisa A.
FUTURE ONCOLOGY, 2021, 17 (30) : 3911 - 3924
[7] Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
Rugo, Hope S.
Tolaney, Sara M.
Loirat, Delphine
Punie, Kevin
Bardia, Aditya
Hurvitz, Sara A.
O'Shaughnessy, Joyce
Cortes, Javier
Dieras, Veronique
Carey, Lisa A.
Gianni, Luca
Piccart, Martine J.
Loibl, Sibylle
Goldenberg, David M.
Hong, Quan
Olivo, Martin
Itri, Loretta M.
Kalinsky, Kevin
NPJ BREAST CANCER, 2022, 8 (01)
[8] Biomarker Evaluation in the Phase 3 ASCENT Study of Sacituzumab Govitecan vs Chemotherapy in Patients With Metastatic Triple-Negative Breast Cancer
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 6 - 7
[9] Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
Hurvitz, Sara A.
Tolaney, Sara M.
Punie, Kevin
Loirat, Delphine
Oliveira, Mafalda
Kalinsky, Kevin
Zelnak, Amelia
Aftimos, Philippe
Dalenc, Florence
Sardesai, Sagar
Hamiltion, Erika
Sharma, Priyanka
Recalde, Sabela
Gil, Eva Ciruelos
Traina, Tiffany
O'Shaughnessy, Joyce
Cortes, Javier
Tsai, Michaela
Vahdat, Linda
Dieras, Veronique
Carey, Lisa
Rugo, Hope S.
Goldenberg, David M.
Hong, Quan
Olivo, Martin
Itri, Loretta M.
Bardia, Aditya
CANCER RESEARCH, 2021, 81 (04)
[10] Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
Lisa A. Carey
Delphine Loirat
Kevin Punie
Aditya Bardia
Véronique Diéras
Florence Dalenc
Jennifer R. Diamond
Christel Fontaine
Grace Wang
Hope S. Rugo
Sara A. Hurvitz
Kevin Kalinsky
Joyce O’Shaughnessy
Sibylle Loibl
Luca Gianni
Martine Piccart
Yanni Zhu
Rosemary Delaney
See Phan
Javier Cortés
npj Breast Cancer, 8

← 1 2 3 4 5 →